Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Oral hypoglycemic agents"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review
Clinical Diabetes & Therapeutics
Article image
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
Diabetes Metab J. 2017;41(5):357-366.   Published online October 24, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.5.357
  • 8,924 View
  • 189 Download
  • 20 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

Citations

Citations to this article as recorded by  
  • Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications
    Neha V. Bhilare, Rushikesh Shedge, Prashant M. Tambe, Ajinkya More
    Medicinal Chemistry Research.2024; 33(3): 337.     CrossRef
  • Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data
    Ariane Jullien, Clément Jambon-Barbara, Jean-Luc Cracowski, Brian L. Claggett, Anne-Laure Borel, Charles Khouri, Matthieu Roustit
    Diabetes Care.2024; 47(11): 1949.     CrossRef
  • Advances in structure-hypoglycemic activity relationship and mechanisms of berry polysaccharides
    Su Jiang-Peng, Fang Jia-Qin, Liu Chuang, Liu Shou-Ping, Chen Chun, Tan Chin-Ping, Wang Ping-Ping, Peng Yun-Ping, Fu Xiong
    Food Bioscience.2024; 62: 105472.     CrossRef
  • Simultaneous Estimation of Repaglinide and Voglibose in Newly Approved Fixed-Dose Combination by using UFLC: Application to ICH Q14 Concept and Comparative Method Greenness Assessment
    S.S. Panda, P.C. Rauta, V.S. Pulusu, S. Sahu, B.B. Dash
    Asian Journal of Chemistry.2023; 35(4): 887.     CrossRef
  • Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
    Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav
    International Journal of Diabetes in Developing Countries.2023; 43(6): 856.     CrossRef
  • The Gut Microbiome, Metformin, and Aging
    Sri Nitya Reddy Induri, Payalben Kansara, Scott C. Thomas, Fangxi Xu, Deepak Saxena, Xin Li
    Annual Review of Pharmacology and Toxicology.2022; 62(1): 85.     CrossRef
  • Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial
    Wajiha Mahjabeen, Dilshad Ahmed Khan, Shakil Ahmed Mirza
    Complementary Therapies in Medicine.2022; 66: 102819.     CrossRef
  • Letrozole: Pharmacology, toxicity and potential therapeutic effects
    Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Dhanushya Nagarajan, Vibhaa K K, Anagha V, Joshua Paul P, Tharani Priya T, Rituraj Chakraborty, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan
    Life Sciences.2022; 310: 121074.     CrossRef
  • Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
    Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
    Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
  • Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non‐interventional comparative study
    Sirajudeen Shaik Alavudeen, Sultan M. Alshahrani, Easwaran Vigneshwaran, Noohu Abdulla Khan, Javid I. Mir, Abubakr T. M. Hussein
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus
    Antonios Kousaxidis, Anthi Petrou, Vasiliki Lavrentaki, Maria Fesatidou, Ioannis Nicolaou, Athina Geronikaki
    European Journal of Medicinal Chemistry.2020; 207: 112742.     CrossRef
  • Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
    Hannah Seok, Tae Seo Sohn
    Diabetes & Metabolism Journal.2019; 43(4): 545.     CrossRef
  • A Survey of the Structures of US FDA Approved Combination Drugs
    Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, Jon T. Njardarson
    Journal of Medicinal Chemistry.2019; 62(9): 4265.     CrossRef
  • Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets
    Marianne A. Mahrouse, Nesrine T. Lamie
    Microchemical Journal.2019; 147: 691.     CrossRef
  • The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea
    Da Young Lee, Ji Hee Yu, Sanghyun Park, Kyungdo Han, Nam Hoon Kim, Hye Jin Yoo, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim, Ji A. Seo
    Scientific Reports.2018;[Epub]     CrossRef
  • Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India
    Nikhilesh Pradhan, Sidhartha Das, Anoj Kumar Baliarsinha, Ashirbad Parhi, Bijan Patnaik, Pramod Kumar Rout
    Journal of Diabetes Mellitus.2018; 08(02): 9.     CrossRef
  • Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program
    Ja Young Jeon, Soo Jin Lee, Sieun Lee, Soo Jin Kim, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Young Seol Kim, Jeong Taek Woo, Kyu Jeung Ahn, Moonsuk Nam, Sei Hyun Baik, Yongsoo Park, Kwan‐Woo Lee
    Journal of Diabetes Investigation.2018; 9(5): 1144.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP